Perry, George

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.

PNA'S AS MODULATORS OF PRESENILIN EXPRESSION

Golde, Todd E

1 May 2000 - 30 April 2001
NATIONAL INSTITUTE ON AGING
Total Funding: $ 76,500

This research application proposes experiments to follow up on a discovery in the Co-PI's laboratory that extracranially administered, carrier-free polyamide ("peptide") nucleic acids (PNAs) targeted to genes (either as an antisense or sense molecule), pass the blood brain barrier and the plasma membrane barrier of neurons, where they specifically inhibit the synthesis of proteins (1). This discovery has the potential of leading to the development of PNA based therapeutics that can treat a multitude of age related diseases. To extend these initial findings to genes thought to be involved in the pathogenesis of Alzheimer's disease (AD), this proposal outlines experiments that will determine whether sense or antisense PNAs targeting the mouse presenilin 1 (PS1) gene reduce presenilin expression and lead to alterations in production of the amyloid beta protein (Abeta) both in vitro and in vivo. At the present time the rules governing optimal design of a PNA targeting a particular gene are not known. We will therefore systematically evaluate the efficacy of a number of PNAs targeting different regions of the mouse presenilin 1 gene in a cell culture system. PS1 PNAs, selected based on their in vitro efficacy (as assessed by effects on PS1 protein levels and Abeta production), will then be administered by i. p injection into Tg2576 transgenic mice that are the only widely available mouse model of amyloid deposition. These experiments should i) provide vital information regarding antisense and antigene PNA design, ii) determine whether PS1 is a reasonable therapeutic target in AD, and iii) in the event that PS1 targeted PNAs lower Abeta production in vivo may eventually lead to a novel therapeutic approach to the treatment of AD.

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.